title: Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: basic aspects and clinical applications.
abstract: Heparanase is an endo-β-D-glucuronidase that cleaves heparan sulfate (HS) side chains at a limited number of sites, activity that is strongly implicated with cell invasion associated with cancer metastasis, a consequence of structural modification that loosens the extracellular matrix barrier. Heparanase activity is also implicated in neovascularization, inflammation, and autoimmunity, involving migration of vascular endothelial cells and activated cells of the immune system. The cloning of a single human heparanase cDNA 10 years ago enabled researchers to critically approve the notion that HS cleavage by heparanase is required for structural remodeling of the extracellular matrix (ECM), thereby facilitating cell invasion. Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells confers an invasive phenotype in experimental animals. The enzyme also releases angiogenic factors residing in the tumor microenvironment and thereby induces an angiogenic response in vivo. Heparanase up-regulation correlates with increased tumor vascularity and poor postoperative survival of cancer patients. These observations, the anticancerous effect of heparanase gene silencing and of heparanase-inhibiting molecules, as well as the unexpected identification of a single functional heparanase suggest that the enzyme is a promising target for anticancer drug development. Progress in the field expanded the scope of heparanase function and its significance in tumor progression and other pathologies such as inflammatory bowel disease and diabetic nephropathy. Notably, while heparanase inhibitors attenuated tumor progression and metastasis in several experimental systems, other studies revealed that heparanase also functions in an enzymatic activity-independent manner. Thus, point-mutated inactive heparanase was noted to promote phosphorylation of signaling molecules such as Akt and Src, facilitating gene transcription (i.e. VEGF) and phosphorylation of selected Src substrates (i.e. EGF receptor). The concept of enzymatic activity-independent function of heparanase gained substantial support by elucidation of the heparanase C-terminus domain as the molecular determinant behind its signaling capacity and the identification of a human heparanase splice variant (T5) devoid of enzymatic activity, yet endowed with protumorigenic characteristics. Resolving the heparanase crystal structure will accelerate rational design of effective inhibitory molecules and neutralizing antibodies, paving the way for advanced clinical trials in patients with cancer and other diseases involving heparanase.
authors.affiliation: Cancer and Vascular Biology Research Center, Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel; and.
authors.forename: Israel
authors.initials: I
authors.lastname: Vlodavsky
authors.forename: Michael
authors.initials: M
authors.lastname: Elkin
authors.forename: Neta
authors.initials: N
authors.lastname: Ilan
keywords: C-domain; Heparanase; angiogenesis; extracellular matrix; heparan sulfate; inflammation; matrix metalloproteinase; metastasis; myeloma; signaling
references.citation: Int Rev Cell Mol Biol. 2009;276:105-59
references.pmid: 19584012
references.citation: Biochem Biophys Res Commun. 2000 Oct 5;276(3):1170-7
references.pmid: 11027606
references.citation: Clin Exp Metastasis. 2008;25(2):149-59
references.pmid: 18027090
references.citation: Mod Pathol. 2009 Dec;22(12):1548-54
references.pmid: 19749739
references.citation: Semin Cancer Biol. 2002 Jun;12(3):173-86
references.pmid: 12083848
references.citation: J Clin Invest. 2009 Nov;119(11):3311-21
references.pmid: 19809157
references.citation: Annu Rev Biochem. 1999;68:729-77
references.pmid: 10872465
references.citation: Curr Protoc Cell Biol. 2001 May;Chapter 10:Unit 10.4
references.pmid: 18228298
references.citation: Biochem Biophys Res Commun. 2007 Oct 5;361(4):829-34
references.pmid: 17689495
references.citation: Cancer Res. 2009 May 1;69(9):3755-63
references.pmid: 19383910
references.citation: Cell Mol Life Sci. 2004 May;61(9):1016-24
references.pmid: 15112050
references.citation: Cancer Res. 2003 Dec 15;63(24):8749-56
references.pmid: 14695190
references.citation: J Cell Mol Med. 2011 Sep;15(9):1857-64
references.pmid: 21029368
references.citation: Cancer Res. 1983 Jun;43(6):2704-11
references.pmid: 6601984
references.citation: Nat Med. 1999 Jul;5(7):793-802
references.pmid: 10395325
references.citation: Matrix Biol. 2004 Oct;23(6):341-52
references.pmid: 15533755
references.citation: FEBS J. 2010 Oct;277(19):3890-903
references.pmid: 20840586
references.citation: Kidney Int. 2007 Sep;72(5):543-8
references.pmid: 17519955
references.citation: Nat Med. 1999 Jul;5(7):735-6
references.pmid: 10395313
references.citation: Cell. 2010 Apr 2;141(1):52-67
references.pmid: 20371345
references.citation: Nat Med. 1998 Jun;4(6):691-7
references.pmid: 9623978
references.citation: J Biol Chem. 2005 Dec 2;280(48):40066-73
references.pmid: 16192265
references.citation: Blood. 2010 Sep 16;116(11):1924-31
references.pmid: 20530797
references.citation: Science. 1983 May 6;220(4597):611-3
references.pmid: 6220468
references.citation: Cancer Sci. 2004 Jul;95(7):553-8
references.pmid: 15245589
references.citation: Biochemistry. 2004 Feb 24;43(7):1862-73
references.pmid: 14967027
references.citation: Neoplasia. 2008 Sep;10(9):977-86
references.pmid: 18714399
references.citation: Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36
references.pmid: 20027185
references.citation: Nat Rev Cancer. 2002 Jul;2(7):521-8
references.pmid: 12094238
references.citation: Pathophysiol Haemost Thromb. 2008;36(3-4):195-203
references.pmid: 19176992
references.citation: Oncogene. 2002 May 9;21(20):3130-8
references.pmid: 12082628
references.citation: J Biol Chem. 1982 Sep 10;257(17):10278-82
references.pmid: 7107605
references.citation: Nat Med. 1999 Jul;5(7):803-9
references.pmid: 10395326
references.citation: Nephrology (Carlton). 2005 Apr;10(2):167-73
references.pmid: 15877677
references.citation: Science. 2002 Mar 29;295(5564):2387-92
references.pmid: 11923519
references.citation: FASEB J. 2005 Feb;19(2):211-21
references.pmid: 15677344
references.citation: Blood. 2007 Jun 1;109(11):4914-23
references.pmid: 17339423
references.citation: J Thromb Haemost. 2007 Apr;5(4):729-37
references.pmid: 17408406
references.citation: Annu Rev Biochem. 1998;67:609-52
references.pmid: 9759499
references.citation: Cancer Res. 2007 Aug 15;67(16):7841-9
references.pmid: 17699790
references.citation: Biochemistry. 2000 Dec 26;39(51):15659-67
references.pmid: 11123890
references.citation: Sci Am. 1996 Sep;275(3):72-7
references.pmid: 8701296
references.citation: J Am Soc Nephrol. 2004 Jan;15(1):68-78
references.pmid: 14694159
references.citation: J Natl Cancer Inst. 2004 Aug 18;96(16):1219-30
references.pmid: 15316057
references.citation: Semin Cell Dev Biol. 2001 Apr;12(2):89-98
references.pmid: 11292374
references.citation: PLoS One. 2009;4(4):e5181
references.pmid: 19360105
references.citation: J Clin Invest. 2001 Jul;108(2):165-7
references.pmid: 11457866
references.citation: J Biol Chem. 2005 Apr 8;280(14):13568-75
references.pmid: 15659389
references.citation: Int J Cancer. 2006 Apr 1;118(7):1609-17
references.pmid: 16217746
references.citation: Cancer Immunol Immunother. 2009 Jun;58(6):887-900
references.pmid: 18998129
references.citation: Nat Rev Mol Cell Biol. 2005 Jul;6(7):530-41
references.pmid: 16072037
references.citation: Invest New Drugs. 2010 Jun;28(3):276-83
references.pmid: 19357810
references.citation: Biochim Biophys Acta. 2001 Mar 21;1471(3):M99-108
references.pmid: 11250066
references.citation: Exp Cell Res. 2008 Sep 10;314(15):2834-45
references.pmid: 18662687
references.citation: Connect Tissue Res. 2008;49(3):207-10
references.pmid: 18661344
references.citation: J Biol Chem. 2008 Jun 27;283(26):18167-76
references.pmid: 18450756
references.citation: Curr Pharm Des. 2007;13(20):2057-73
references.pmid: 17627539
references.citation: Perspect Dev Neurobiol. 1996;3(4):359-71
references.pmid: 9117266
references.citation: Semin Cancer Biol. 2005 Oct;15(5):378-86
references.pmid: 15975825
references.citation: Cancer Res. 2006 Feb 1;66(3):1455-63
references.pmid: 16452201
references.citation: Mod Pathol. 2007 Jan;20(1):8-14
references.pmid: 17041566
references.citation: Annu Rev Biochem. 1991;60:443-75
references.pmid: 1883201
references.citation: Int J Biochem Cell Biol. 2006;38(12):2018-39
references.pmid: 16901744
references.citation: Am J Pathol. 2000 Oct;157(4):1167-75
references.pmid: 11021821
references.citation: J Biol Chem. 1998 Jul 24;273(30):18770-7
references.pmid: 9668050
references.citation: FASEB J. 2010 Apr;24(4):1239-48
references.pmid: 20007507
references.citation: Semin Thromb Hemost. 2007 Jul;33(5):557-68
references.pmid: 17629854
references.citation: Cancer Metastasis Rev. 1990 Nov;9(3):203-26
references.pmid: 1705486
references.citation: J Biol Chem. 2008 Nov 21;283(47):32628-36
references.pmid: 18812315
references.citation: J Biol Chem. 1975 Apr 10;250(7):2690-7
references.pmid: 804478
references.citation: Nat Rev Cancer. 2009 Apr;9(4):274-84
references.pmid: 19308067
references.citation: Cancer Metastasis Rev. 1996 Jun;15(2):177-86
references.pmid: 8842489
references.citation: Crit Rev Oncol Hematol. 2008 Oct;68(1):12-28
references.pmid: 18396408
references.citation: Nature. 1981 Jan 22;289(5795):304-6
references.pmid: 7453826
references.citation: Annu Rev Biochem. 1986;55:1037-57
references.pmid: 3017189
references.citation: Bioessays. 1996 Feb;18(2):123-32
references.pmid: 8851045
references.citation: J Med Chem. 2005 Dec 29;48(26):8229-36
references.pmid: 16366604
references.citation: Development. 2007 Dec;134(23):4177-86
references.pmid: 17959718
references.citation: Cell. 1980 Mar;19(3):607-16
references.pmid: 6965887
references.citation: J Clin Invest. 2001 Aug;108(3):341-7
references.pmid: 11489924
references.citation: Trends Biochem Sci. 1991 Jul;16(7):268-71
references.pmid: 1926336
references.citation: Trends Biochem Sci. 2009 Oct;34(10):511-9
references.pmid: 19733083
references.citation: Nat Rev Drug Discov. 2007 Apr;6(4):273-86
references.pmid: 17396134
references.citation: J Biol Chem. 2007 May 4;282(18):13326-33
references.pmid: 17347152
references.citation: Mini Rev Med Chem. 2004 Aug;4(6):693-702
references.pmid: 15279603
references.citation: J Cell Physiol. 2008 Dec;217(3):643-51
references.pmid: 18636552
references.citation: FASEB J. 2001 Jul;15(9):1661-3
references.pmid: 11427519
references.citation: Am J Pathol. 1988 Feb;130(2):393-400
references.pmid: 3277442
references.citation: Cancer Immunol Immunother. 2010 Jul;59(7):1041-7
references.pmid: 20182872
references.citation: FASEB J. 2007 Nov;21(13):3562-72
references.pmid: 17557930
references.citation: Blood. 2000 Jan 15;95(2):388-92
references.pmid: 10627439
references.citation: Arthritis Rheum. 2008 Jun;58(6):1590-600
references.pmid: 18512775
references.citation: Invasion Metastasis. 1992;12(2):112-27
references.pmid: 1399400
references.citation: Blood. 2007 Sep 15;110(6):2041-8
references.pmid: 17536013
references.citation: Blood. 2010 Mar 18;115(11):2319-28
references.pmid: 20075159
references.citation: Biochem Biophys Res Commun. 2003 Sep 5;308(4):885-91
references.pmid: 12927802
references.citation: Trends Biochem Sci. 2003 Mar;28(3):145-51
references.pmid: 12633994
references.citation: Cancer Metastasis Rev. 2009 Jun;28(1-2):167-76
references.pmid: 19160017
references.citation: Int J Cancer. 2008 Dec 1;123(11):2566-73
references.pmid: 18798279
references.citation: J Biol Chem. 2004 May 28;279(22):23536-41
references.pmid: 15044433
references.citation: Proc Natl Acad Sci U S A. 1987 Apr;84(8):2292-6
references.pmid: 3470794
references.citation: Biochemistry. 1989 Feb 21;28(4):1737-43
references.pmid: 2541764
references.citation: Blood. 2006 May 1;107(9):3609-16
references.pmid: 16384929
references.citation: J Biol Chem. 1991 May 25;266(15):9661-6
references.pmid: 2033058